Take a quick look at everything you may have missed last month, including the latest FDA updates and top stories.

A large European study finds that exposure to fine particulate matter during pregnancy may increase the risk of childhood overweight and obesity, especially in children aged 9 to 12 years.

Uterine fibroid care is evolving with more treatment options, fertility-focused planning, and a greater emphasis on quality of life and shared decision-making.

New research shows that analyzing sleep pattern variability from wearable devices can improve early prediction of preterm birth in pregnant women.

Experts warn that removing the COVID-19 vaccine from CDC guidelines endangers maternal and neonatal health and undermines evidence-based medical practice.

A new study finds women with postpartum hemorrhage face significantly higher odds of cardiovascular disease and thromboembolism for up to 15 years after childbirth.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A panelist emphasizes that effectively managing endocrine therapy adverse effects—particularly vasomotor symptoms—can significantly improve treatment adherence, which is critical for reducing recurrence risk and improving survival in patients with breast cancer.

A panelist shares that secondary results from the trial showed early and sustained improvements in sleep and quality of life, underscoring the therapy’s potential to enhance endocrine treatment adherence by alleviating vasomotor symptoms (VMS) that often lead to poor adherence in patients with breast cancer.

A new study reveals rising breast cancer rates among minority women aged 65 to 74 years, highlighting the need for targeted screening and intervention strategies.

Women with attention-deficit hyperactivity disorder are over 3 times more likely to experience premenstrual dysphoric disorder, especially when co-occurring with anxiety or depression, according to new research.

A new study reveals that abnormal postpartum bleeding is more common than previously reported, driving up hospital costs and increasing the risk of serious complications.

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

New research shows women receiving Medicaid and support services are significantly more likely to receive treatment for opioid and drug use disorders.

A new study reveals that nearly half of women who want kids are uncertain they'll follow through, shedding light on the complex emotions behind declining birth rates.

A major clinical trial shows personalized treatment based on molecular profiling can safely cut radiation use in nearly half of women with high-intermediate risk endometrial cancer.

Researchers developed a CRISPR-Select assay to classify BRCA gene variants, improving early breast and ovarian cancer detection.

A new study finds that exposure to mycoestrogens during pregnancy may reduce birthweight and impair placental efficiency, with climate change expected to increase exposure risks.

The American Medical Association urges plant-based diets, exercise, and reduced alcohol to lower breast cancer risk and address racial disparities.

Wildfire smoke and heat stress before and early in pregnancy raise the risk of SGA births, especially in climate-vulnerable neighborhoods.

Higher third-trimester glucose levels in insulin-dependent pregnancies are tied to increased obesity risk in adult offspring, a 40-year study finds.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A new study reveals how provider bias and stigma in reproductive health settings limit care for young, unmarried, and childless women—and how targeted interventions can help reduce these barriers.

A panelist highlights that at ASCO 2025, a landmark phase 3 trial showed a new treatment significantly reduced moderate-to-severe hot flashes in patients with breast cancer receiving endocrine therapy, with rapid and sustained symptom relief and high patient continuation rates over 2 years.

A panelist explains that although hormone replacement therapy is contraindicated in patients with breast cancer due to recurrence risks, new nonhormonal treatments targeting neurokinin receptors in the brain offer promising relief for vasomotor symptoms without interfering with endocrine therapy.